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Heme oxygenase (HO; EC 1:14.99.3, heme, hydrogen donor:
oxygen oxidoreductase (𝛼-methene hydroxylating, decycliz-
ing)) catalyzes the rate limiting the step in the oxidative
catabolism of heme to generate biliverdin-IX𝛼, which is sub-
sequently converted to bilirubin-IX𝛼 by cytosolic NAD(P)H-
dependent biliverdin reductase [1]. This reaction, which
requiresmolecular oxygen as well as electrons fromNADPH-
dependent cytochrome p-450 reductase, liberates the small
gas mediator carbon monoxide (CO) and ferrous iron [1].
The constitutive form of this enzyme (HO-2) is expressed
highly in neuronal and vascular tissues, whereas the inducible
form of this enzyme (HO-1) is recognized as a major stress-
inducible protein in mammalian cells [2]. HO-1 induction
represents a general inducible response in cells and tissues by
a broad range of chemical and physical stress agents [3], and
it is transcriptionally regulated in response to these agents
primarily by the Keap1–Nrf2 system, amaster regulator of the
oxidative stress response [4].
The inducible form of HO, heme oxygenase-1 (HO-
1), confers protection against oxidative stress conditions in
vitro and in vivo [5]. Although the mechanisms of HO-1-
dependent cytoprotection remain incompletely understood,
accumulating evidence has implicated contributory roles
for the products generated from HO activity. Biliverdin
and bilirubin are potent antioxidant compounds, whereas
iron liberated from HO activity stimulates the produc-
tion of ferritin, a cytoprotective molecule [6]. Previously
regarded as metabolic waste, CO may affect intracellu-
lar signaling pathways [7]. Exogenously applied CO can
mimic the cytoprotective effects of HO-1 [8], involving the
modulation of cellular redox state as well as the regula-
tion of apoptosis, inflammation, and cellular proliferation
[9].
In recent years, it has become clear that the HO-1/CO
system can potentially impact cellular metabolic pathways.
The cardinal example is the clearance of intracellular heme by
the catabolic activity of HO-1 [1], leading to the redistribution
of cellular iron [6, 10]. In this special issue, we sought to invite
papers that explore the novel aspects of the HO-1/CO system
with respect to the regulation of metabolic pathways.
It is increasingly recognized that the mitochondria, the
central energy generating organelle of the cell, can play
important roles not only in metabolism but also in the
regulation of cellular programs, including apoptosis and
inflammation, and that mitochondrial dysfunction may be
a key component of human diseases [11]. Recent studies
have implicated HO-1/CO as important regulators of mito-
chondrial biogenesis and mitochondrial function [12, 13].
The paper by N. Rayamajhi et al., published in this special
issue, demonstrates that the natural antioxidant quercetin, a
plant derived flavonoid, enhances mitochondrial biogenesis
through the activation of the HO-1/CO system in hepato-
cytes and furthermore prevents the decline of mitochondrial
biogenesis in an in vivo model of sepsis. These studies lend
support to the notion that natural dietary antioxidants, such
as quercetin, could be used as pharmacological inducers of
HO-1 and for the preservation of mitochondrial function for
the treatment of disease.
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The role of the HO-1/CO system in the regulation of
lipid metabolism is not well studied. The paper by S.-J. Lee
et al. demonstrates that mitochondrial dysfunction under
cellular stress conditions is associated with the disruption of
lipid metabolism and the formation of lipid droplets (LD).
Using HO-1 deficient mice, the authors uncover a previously
unknown role for HO-1 in LD formation during polymicro-
bial sepsis.These results strongly suggest thatHO-1 also influ-
ences lipid metabolism in response to mitochondrial dys-
function and as a part of the cytoprotective response to stress.
In addition to lipids, polyamines are ubiquitous cellu-
lar constituents that can influence cell survival and death
pathways. The relationship between the HO-1/CO system
and polyamine metabolism is largely uncharted. The paper
by H. Yang et al. demonstrates that spermidine, a cellular
polyamine, can induce HO-1 in endothelial cells, through
the Nrf2 pathway. The induction of HO-1 provides cellular
antiapoptotic protection against the toxic effects of exogenous
spermidine. These results affirm the antiapoptotic potential
of HO-1 against natural apoptosis-inducing compounds and
uncover a novel effect of polyamines on HO-1 regulation.
It is generally recognized that HO-1/CO can provide
protection in animal models of ischemia reperfusion injury
and cardiovascular disease. In humans, susceptibility to
ischemic disease is greater in males than in females. The
paper by A. Po´sa et al. explores the possibility that differences
in HO-1 expression may account for gender differences in
susceptibility to ischemic disease.The authors report that the
differential HO activity may be responsible for the resistance
of female versus male mice to cardiovascular disruption and
vasoconstriction during ischemia.
The therapeutic potential of CO has gained momentum
in recent years and is summarized in the article by M.
Knauert et al. The authors describe the intracellular sig-
naling pathways that can be modulated by CO including
mitogen activated protein kinases, nuclear factor 𝜅-B, and
the phosphatidylinositol-3-kinase/Akt pathway, which are
involved in the regulation of inflammation and cell survival.
Furthermore, the authors discuss the evolution of the field
from animal modeling, in which CO has demonstrated tissue
protective effects in lung injury and sepsis models, to its
prospective use in the clinical arena as a therapy for human
diseases. Although the latter goal is not yet realized, current
efforts aim to characterize the efficacy of CO therapy for
human sepsis.
We hope that the articles presented in this special issue,
representing current advances in the HO-1/CO field, with
respect to their potential impact in metabolic pathways, will
stimulate further exploration of this exciting area.
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